share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer Hirawat Samit

SEC announcement ·  Mar 13 08:44
Summary by Futu AI
On March 10, 2024, Samit Hirawat, EVP, Chief Medical Officer, and Head of Drug Development at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Hirawat acquired a total of 38,388 shares through the exercise of derivative securities at no cost. Concurrently, he disposed of 25,354 shares. The disposals included shares used to cover exercise prices or tax liabilities, with some transactions priced at $53.79 per share, resulting in a total market value of $734,179.71. Following these transactions, Hirawat's direct holdings in Bristol-Myers Squibb common stock amounted to 60,279 shares.
On March 10, 2024, Samit Hirawat, EVP, Chief Medical Officer, and Head of Drug Development at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Hirawat acquired a total of 38,388 shares through the exercise of derivative securities at no cost. Concurrently, he disposed of 25,354 shares. The disposals included shares used to cover exercise prices or tax liabilities, with some transactions priced at $53.79 per share, resulting in a total market value of $734,179.71. Following these transactions, Hirawat's direct holdings in Bristol-Myers Squibb common stock amounted to 60,279 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.